Nausheen Ahmed

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

28h-index4.5kcitations380works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(159), Multiple Myeloma Research and Treatments(102), Biosimilars and Bioanalytical Methods(43), Hematopoietic Stem Cell Transplantation(40), Protein Degradation and Inhibitors(39)

Publications370 total

Response to letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database
European Journal of Cancer·2025
Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study
Transplantation and Cellular Therapy·2025
Outcomes after bone marrow versus peripheral blood haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis
Hematology Transfusion and Cell Therapy·2025Open Access
Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials
Cancers·2025Open Access
Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study
Blood Cancer Journal·2025Open Access
Utility of neurotoxicity investigations in CD19 and BCMA CART recipients with ICANS
Blood Immunology & Cellular Therapy·2025Open Access
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Cancers·2025· 1 citedOpen Access
Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis
Blood·2025Open Access
Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications
Blood·2025Open Access
Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study
Blood·2025
Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Blood·2025Open Access
Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis
Blood·2025
The durability of consolidative transplant in mediastinal gray zone lymphoma, a single institution retrospective
Blood·2025Open Access
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis
Blood·2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Haematologica·2025Open Access
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
Transplantation and Cellular Therapy·2025· 1 citedOpen Access
Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database
European Journal of Cancer·2025· 3 cited
CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective
Current Oncology·2025Open Access
Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: A Center for International Blood & Marrow Transplantation Research (CIBMTR) Study
Clinical Lymphoma Myeloma & Leukemia·2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 19Next →

Frequent Co-authors

Joseph P. McGuirk(23), Al‐Ola Abdallah(14), Hamza Hashmi(12), Muhammad Umair Mushtaq(11), Leyla Shune(11), James A. Davis(11), Danai Dima(9), Faiz Anwer(9), Moazzam Shahzad(8), Zahra Mahmoudjafari(8), Mehdi Hamadani(8), Jack Khouri(8), Peiman Hematti(7), Peter A. Riedell(7), Shahzad Raza(7), Sibgha Gull Chaudhary(7), Anurag K. Singh(7), William Wesson(7), Marcos de Lima(6), Veronika Bachanová(6)